Celltrion (068270) Q3 2025 earnings summary

Executive summary

• Achieved record quarterly sales exceeding KRW 1 trillion and operating profit over KRW 300 billion in 3Q25, driven by high-margin young biologics products.

• Consolidated revenue for the first nine months of 2025 was KRW 2,832.3 billion, with operating income of KRW 693.3 billion and an operating margin of 24.5%.

• Net income attributable to owners was KRW 501.2 billion, with basic EPS of KRW 2,265.

• Completed integration of Celltrion Healthcare, streamlining global sales and distribution.

• Maintained strong cash position with KRW 810.0 billion in cash and cash equivalents at quarter-end.

Financial highlights

• 3Q25 sales: KRW 1,029 billion (+16.7% YoY, +7.0% QoQ); operating profit: KRW 301.4 billion (+45.1% YoY, +24.3% QoQ); OP margin: 29.3% (+4.1%p YoY).

• Net profit for 3Q25: KRW 332 billion, net profit margin: 32.3% (up 22.8%p YoY).

• Gross profit margin reached 60.8% in 3Q25, up 8.3%p YoY.

• R&D expenses were KRW 353.3 billion, representing 12.5% of sales.

• Cash dividends paid in 2025 totaled KRW 153.8 billion, with a stock dividend of KRW 10.3 billion.

Outlook and guidance

• Product mix expected to shift further toward high-margin young products in 4Q25 and beyond.

• Profitability anticipated to improve with additional launches (Eydenzelt, Avtozma) and expanded prescriptions for 2025 launches.

• Five new product launches by end of 2025 to expand addressable market from $55B to $103B.

• 2025 sales target set at KRW 5 trillion, with continued focus on biosimilar and new drug launches.

• CDMO business expansion underway, including new U.S. manufacturing site acquisition.